Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Document Type
Journal Article
Publication Date
9-1-2015
Journal
Journal of Immunotherapy
Volume
38
Issue
7
Inclusive Pages
299-305
DOI
10.1097/CJI.0000000000000088
Keywords
Antigens, CD19--immunology; Antineoplastic Agents--therapeutic use; B-Lymphocytes--immunology; Immunotoxins--immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma--immunology; Ribosome Inactivating Proteins, Type 1--immunology
APA Citation
Meany, H.J., Seibel, N.L., Krailo, M., Villaluna, D., Chen, Z. et al. (2015). Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. Journal of Immunotherapy, 38(7), 299-305.
Peer Reviewed
1
Comments
PMCID: PMC4536569 [Available on 2016-09-01]